Trial site
Urology Centers of Alabama
Homewood, Alabama 35209, United StatesNot linked to an institution yet
- 12running trials
- 1closed trial
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 22 trials
- Status
- Active, not recruiting8 trials
- Recruiting4 trials
- Completed1 trial
- Lead sponsor
- Janssen Research & Development, LLC3 trials
- Bayer1 trial
- Curium US LLC1 trial
- Lantheus Medical Imaging1 trial
- Myriad Genetic Laboratories, Inc.1 trial
- and 6 more
Running trials
Recruiting
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
NCT06774131· Phase 3· UroGen Pharma Ltd.· Source
Contact: Rita Aderholt
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677· Phase 2· Tyra Biosciences, Inc· Source
Contact: Gina Risdall
Recruiting
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
NCT06394869· Pacific Edge Limited· Source
Contact: Meredith A Sharpton, PA-C
Active, not recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· Phase 3· Pfizer· Source
Active, not recruiting
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151· Phase 3· Curium US LLC· Source
Recruiting
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
NCT05951179· Phase 2· Protara Therapeutics· Source
Contact: Chief Scientific Operations Officer
Active, not recruiting
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer
NCT05712473· Lantheus Medical Imaging· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
NCT04404894· Myriad Genetic Laboratories, Inc.· Source
Active, not recruiting
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
NCT04122976· Bayer· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error